Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2018
This study will evaluate the efficacy of uproleselan (GMI‐1271), a specific E‐selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML
Epistemonikos ID: 331beef546d067be09da21bfcd422f4984b31de4
First added on: Jan 21, 2022